Wide Neck Bifurcation Intracranial Aneurysms Clinical Trial
— WEB-IT ChinaOfficial title:
WEB® Intrasaccular Therapy Study China Clinical Trial Protocol
Verified date | October 2020 |
Source | Sequent Medical, Inc |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This trial is a prospective, multicenter, single-arm confirmatory clinical trial. The study is to confirm the safety and effectiveness of the WEB Aneurysm Embolization System demonstrated in the US WEB-IT Study for the treatment of intracranial wide-neck bifurcation aneurysms. The study's primary endpoints include a primary effectiveness endpoint and a primary safety endpoint. The study device must meet both endpoints. The primary effectiveness endpoint is adjudicated by an independent third party core lab.
Status | Active, not recruiting |
Enrollment | 60 |
Est. completion date | April 30, 2021 |
Est. primary completion date | January 30, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Patient whose age = 18 and =75 years old - Patient must have a single ruptured or unruptured IA(intracranial aneurysm)requiring treatment - Patient must sign and date IRB/EC approved written informed consent prior to initiate of any study procedures Exclusion Criteria: - Patient has an IA with characteristics unsuitable for endovascular treatment - Patient has stroke-in-evolution within the prior 60-days - Patient has had an SAH(subarachnoid hemorrhage) from a nonindex IA or any other intracranial hemorrhage within 90 days - Patient's index IA was previously treated - Patient is pregnant |
Country | Name | City | State |
---|---|---|---|
China | Tiantan Hospital | Beijing | |
China | Xuanwu Hospital, Capital Medical University | Beijing | |
China | West China | Chengdu | Sichuan |
China | The Second affiliated Hospital of Zhejiang University School of Medicine | Hangzhou | |
China | Changhai Hospital Affiliated to The Second Military Medical University ( Shanghai Changhai Hospital) | Shanghai | Shanghai |
China | Huashan Hospital | Shanghai | |
China | The General Hospital of Shenyang Military | Shenyang | |
China | Tangdu Hospital, the Fourth Military Medical University | Xi'an |
Lead Sponsor | Collaborator |
---|---|
Sequent Medical, Inc |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Primary Effectiveness Endpoint: Complete (angiographic) aneurysm occlusion as assessed by Core Lab, without parent artery stenosis | Proportion of complete (angiographic) aneurysm occlusion as assessed by Core Lab without retreatment, recurrent subarachnoid hemorrhage, without significant parent artery stenosis (>50% stenosis) at one year after treatment. | 12 month | |
Primary | Primary Safety Endpoint: Proportion of death and major stroke | Proportion of death of any nonaccidental cause or any major stroke (defined as an ischemic or hemorrhagic stroke resulting in an increase of 4 points or more on the National Institutes of Health Stroke Scale) within the first 30 days after treatment or major ipsilateral stroke or death due to neurologic cause from day 31 to the 1 year after treatment. | 12 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04839705 -
Post Approval Study - Evaluate the Long-Term Safety and Effectiveness of the WEB Device
|
N/A | |
Active, not recruiting |
NCT02191618 -
The WEB-IT Clinical Study
|
N/A |